GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Anxiety Disorder

Treatments: Drug: MK0777

Study type: Interventional

Funder types: Industry

Identifiers

NCT00546624

2007_632

0777-026

Details and patient eligibility

About

This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment: 38 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have been diagnosed with Generalized Anxiety Disorder
• Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study

Exclusion criteria

• History of drug or alcohol abuse
• Have previously participated in another study using MK0777

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind